CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
However, the company has significantly underperformed broader equities in the past five years. The stock is bouncing back, though, and it has had momentum over the trailing-12-month period. Things could get even better as CRISPR Therapeutics makes clinical progress throughout the year. With plenty of catalysts ahead, is now a good time to buy the stock? Image source: Getty Images. Will AI create the world's first trillionaire? Our team just released a report on a little-known company, called an "Indispensable Monopoly," providing the critical technology Nvidia and Intel both need. Continue » Multiple data readouts on the horizon CRISPR Therapeutics is a gene editing specialist . The company's only approved product, Casgevy -- which it commercializes in partnership with Vertex Pharmaceuticals -- has not yet generated much revenue. But CRISPR Therapeutics has a rich pipeline of exciting candidates across several therapeutic areas. Some of the company's products in development
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- CRISPR Therapeutics (CRSP) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Share Price Performance [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (CRSP) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic Area [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 2/12/26 - Miss
CRSP
Sec Filings
- 4/21/26 - Form ARS
- 4/21/26 - Form DEFA14A
- 4/21/26 - Form DEF
- CRSP's page on the SEC website